English Toll-free:1-888-852-8623 or Contact Us
Keyword cannot be empty !

Recombinant Cynomolgus PD-L1/B7-H1/CD274 Protein (Fc Tag)

Cat:PKSQ050046
Manual MSDS

Price: $ 297

Price: $ 111

Size:
50μg 10μg
Quantity:
  • Expression Host: HEK293 Cells
  • Accession: G7PSE7
Add to cart

For research use only. Order now, ship in 3 days

Product Details
Synonyms B7-H;B7H1;B7-H1;B7H1PDCD1L1;CD274 antigenMGC142294;CD274 molecule;CD274;PDCD1L1;PDCD1LG1;PDL1;PD-L1;PD-L1B7 homolog 1;PDL1PDCD1 ligand 1;programmed cell death 1 ligand 1;Programmed death ligand 1
Species Cynomolgus macaques
Expression Host HEK293 Cells
Sequence Phe19-Thr239
Accession G7PSE7
Calculated Molecular Weight 52.4 kDa
Observed Molecular Weight 73 kDa
Tag C-Fc
Purity > 95 % as determined by reducing SDS-PAGE.
Endotoxin < 1.0 EU per μg of the protein as determined by the LAL method.
Storage Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.
Shipping This product is provided as lyophilized powder which is shipped with ice packs.
Formulation Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.
Reconstitution Please refer to the printed manual for detailed information.
Background CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.